Eledon Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Eledon PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 33% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 87.2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-33.0%

Wachstumsrate der Gewinne

-10.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	87.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ELDN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-79	-106	N/A	2
12/31/2025	N/A	-81	-84	N/A	4
12/31/2024	N/A	-20	N/A	N/A	5
9/30/2024	N/A	-25	-37	-37	N/A
6/30/2024	N/A	-89	-38	-38	N/A
3/31/2024	N/A	-129	-38	-38	N/A
12/31/2023	N/A	-117	-40	-40	N/A
9/30/2023	N/A	-145	-40	-40	N/A
6/30/2023	N/A	-145	-32	-32	N/A
3/31/2023	N/A	-89	-30	-30	N/A
12/31/2022	N/A	-88	-28	-28	N/A
9/30/2022	N/A	-38	-28	-28	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-36	-32	-32	N/A
12/31/2021	N/A	-35	-29	-29	N/A
9/30/2021	N/A	-32	-29	-29	N/A
6/30/2021	N/A	-28	-23	-23	N/A
3/31/2021	N/A	-23	-18	-18	N/A
12/31/2020	N/A	-23	-15	-15	N/A
9/30/2020	N/A	-21	-8	-8	N/A
6/30/2020	N/A	-18	-10	-10	N/A
3/31/2020	N/A	-19	-12	-12	N/A
12/31/2019	N/A	-16	-14	-14	N/A
9/30/2019	N/A	-16	-15	-15	N/A
6/30/2019	N/A	-17	-15	-15	N/A
3/31/2019	N/A	-16	-14	-14	N/A
12/31/2018	N/A	-14	-12	-12	N/A
9/30/2018	N/A	-12	-11	-11	N/A
6/30/2018	N/A	-11	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-16	N/A
12/31/2017	N/A	-11	N/A	-15	N/A
9/30/2017	N/A	-9	N/A	-14	N/A
6/30/2017	N/A	-6	N/A	-12	N/A
3/31/2017	N/A	-1	N/A	-5	N/A
12/31/2016	N/A	-1	N/A	-5	N/A
9/30/2016	N/A	-1	N/A	-6	N/A
12/31/2015	N/A	-1	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ELDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ELDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ELDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ELDN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ELDN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ELDN in 3 Jahren voraussichtlich hoch sein wird

Eledon Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 20% to US$12.50

Price target decreased by 10% to US$14.00

Price target decreased by 10% to US$16.50

Price target decreased to US$19.40

Price target decreased to US$28.80

Price target decreased to US$29.75

Recent updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Price target decreased by 10% to US$14.00

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

New minor risk - Share price stability

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Price target decreased by 10% to US$16.50

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Price target decreased to US$19.40

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$28.80

Price target decreased to US$29.75

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought US$89k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon gives update on development strategy for AT-1501 in renal transplantation

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: US$12.66

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

New 90-day low: US$14.76

Price target raised to US$35.00

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics EPS misses by $3.76

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

New 90-day high: US$21.42

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - US$0.41

New 90-day low - US$0.44

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

Gewinn- und Umsatzwachstumsprognosen